Abstract For many types of human cancer, the expression of vascular endothelial growth factor-C
Introduction
Cancer patient prognosis is largely determined by the dissemination of tumor cells, as metastases are responsible directly or indirectly for more than 90 % of all cancer deaths [1, 2] . Systemic dissemination is afforded by the trafficking of tumor cells in the blood and lymphatic vasculature. In the case of the lymphatic system, tumor-associated lymphatic vessels provide a conduit through which disseminating tumor cells are transported to regional lymph nodes [3, 4] . For many types of cancer the presence of regional lymph node metastases has high prognostic significance, as reflected by its central place in tumor staging schemes [5, 6] and the use of sentinel lymphadenectomy to assess prognosis and thus guide the post-operative therapy of cancer patients [7] .
Tumor-induced lymphangiogenesis is an important stimulus for the formation of lymph node metastases [4] . A major regulator of lymphangiogenesis is VEGFR-3, a receptor tyrosine kinase that is expressed on lymphatic endothelial cells and is activated by its ligands VEGF-C and VEGF-D [8] . These growth factors are proteolytically processed during their biosynthesis, which results in an increase in the affinity of VEGF-C for VEGFR-3. The fully processed form can also activate VEGFR-2, albeit less potently than VEGFR-3 [9] . A cysteine point mutation ablates the ability of VEGF-C to activate VEGFR-2 while maintaining its ability to activate VEGFR-3 [10, 11] .
The expression of pro-lymphangiogenic factors such as VEGF-C in many types of tumor correlates with increased tumor-associated LVD, metastasis formation and poor prognosis [4] . In animal models, experimental manipulation of VEGF-C expression or activity, or blocking of VEGFR-3 activation has provided functional evidence that VEGF-C can induce lymphangiogenesis in the context of the primary tumor, and concomitantly promotes metastasis formation in lymph nodes and often other organs [12] [13] [14] [15] [16] [17] [18] [19] . For example, using syngeneic rat breast cancer models, we have shown that ectopic expression of VEGF-C in poorly metastatic NM-081 cells increases tumor-associated LVD and is sufficient to induce metastasis to lymph nodes and lungs [16] . Conversely, blockade of VEGFR-3 activation in highly metastatic MT-450 tumors that express VEGF-C reduces tumor-associated LVD, and at the same time suppresses metastasis formation in both lymph nodes and lungs [16] . Together these data suggest that tumor-induced lymphangiogenesis in the vicinity of primary tumors increases the likelihood that invasive tumor cells will enter the lymphatic vasculature and traffic to regional lymph nodes and beyond.
In addition to acting locally, primary tumor-derived prolymphangiogenic factors have also been reported to induce lymphangiogenesis in the lymph nodes that drain the tumor [20] . In breast cancer, VEGF-C but not VEGF-D draining from tumors has been implicated in tumor-induced lymphangiogenesis [21] , while VEGF-D draining from tumors acts to dilate the collecting lymphatic vessels via prostaglandins [22] . In mice that transgenically express VEGF-C in the skin, chemically induced skin tumors stimulated lymphangiogenesis in their draining lymph nodes before metastatic cells entered the lymph nodes, which was further augmented once metastases formed [23] . Similar findings have been made with other animal models [24, 25] . Correspondingly, human melanomas have been reported to induce lymph node lymphangiogenesis (LNL), and lymphangiogenesis was found in 25 % of non-involved axillary lymph nodes in human breast tumors [26, 27] . LNL also correlates with poor prognosis and metastasis in extramammary Paget's disease [20] . Tumor-induced LNL can increase lymph flow to the lymph node, and it has been suggested that this may foster the formation of lymph node metastases [24] . Nevertheless, it remains to be shown whether the activity of VEGF-C in lymph nodes, for example by inducing lymphangiogenesis or through other mechanisms, plays a functional role in metastasis formation.
Using the NM-081 and MT-450 breast cancer models, we have investigated here whether manipulation of VEGF-C activity in tumor-draining lymph nodes affects metastasis formation. Intradermal delivery of VEGF-C and subsequent ectopic induction of LNL was insufficient to stimulate metastasis formation by poorly metastatic NM-081 tumors. However, lymph node-specific antibodymediated inhibition of VEGFR-3 activation in response to VEGF-C draining to the nodes from metastatic MT-450 tumors inhibited the outgrowth but not initiation of metastases in these nodes. No effect on lung metastasis was observed. These data demonstrate a functional role for tumor-derived VEGF-C within lymph nodes that promotes the outgrowth of lymph node metastases.
Materials and methods

Cells
The NM-081 and MT-450 cell lines cultured as described previously [16] were stably transfected with pcDNA3.1(?)/ mCherry vector or with empty pcDNA3.1(?) using FuGene (Roche) according to the manufacturer's instructions. Cells stably expressing mCherry were enriched by FACS. S2 cells stably expressing either pAc5.1/His/BiP/DNDC/ VEGF-C or pAc5.1/His/BiP/DNDC/VEGF-C Cys were cultured as previously described [11] . Flow cytometry was performed as previously described [16] . Dead cells were excluded using 7-AAD (BD Bioscience). Cells were analysed in 2 % FCS/PBS.
Tumor experiments in vivo
Tumor cells (1 9 10 6 cells per animal) were injected into the 4th mammary fat pad of Wistar Furth (w/Fu) rats aged between 8 and 12 weeks. The volume of the tumors was determined periodically using the formula 4/3p (d 1 /2 9 d 2 / 2 9 d 3 /2), assuming that the shape of the tumor approximates to a sphere, where d 1 -d 3 refers to the diameter in each dimension. At autopsy, the number, size and location of metastases in the draining lymph nodes and other organs were assessed. Tissues were fixed in 4 % PFA/7 % sucrose/6 % picric acid solution, then embedded either in paraffin or in OCT (Sakura Finetek). The presence of metastatic tumor cells in sections was assessed using H&E staining and fluorescence microscopy analysis of mCherry expression. Tumor interstitial fluid was isolated as previously described [28] . The VEGF-C content of tumor interstitial fluid and serum was quantified by ELISA using the rat VEGF-C kit BMS626/2 (Bender MedSystems) according to the manufacturer's instructions. All animal experiments were approved by the local authorities and performed according to German legal requirements.
Immunohistochemistry and morphometric analysis OCT-embedded tissues were cut into 6-8 lm thick sections, dried, then fixed in cold acetone. After blocking with 10 % goat serum in PBS, primary antibody solution containing either 3 lg/ml CD31 (550300, BD, Biosciences), 5 lg/ml LYVE-1 (103-PA50S, Reliatech) or 4 lg/ml Prox1 (102-PA32S, Reliatech) was applied to each slide and incubated at 4°C overnight. The sections were then washed with PBS, and an appropriate secondary antibody coupled to AlexaFluor 488 or 594 (Molecular Probes) was applied. Sections were counterstained with DAPI (4 0 ,6-diamidino-2-phenylindole) for 10 min (0.5 lg/ml), washed with PBS, then mounted in aqueous mounting medium (Fluoromount G-Southern Biotech). Sections were analysed using an AxioVision Image1 microscope (Zeiss). For primary tumor samples, six different fields of 1 mm 2 each per animal were captured and analyzed. For lymph node analysis, high-resolution photomicrographs of the lymph nodes were captured and assembled to construct a complete picture of the entire node. A minimum of four complete lymph node sections were assembled per animal. The pictures were analyzed using ImageD software (Nikon) to calculate the percentage area that was positively stained for each antibody (LYVE-1/CD31), or to calculate the percentage of positively stained nuclei per lymph node section (Prox-1).
Recombinant protein production
Recombinant His-tagged fully processed rat VEGF-C protein (VEGF-C DNDC) and the VEGFR-3-specific point mutant thereof (VEGF-C DNDC Cys) were affinity purified over a Zn-Sepharose column from S2 insect cell conditioned medium as previously described [11] . Protein-containing fractions were tested for the purity of the recombinant protein using gel electrophoresis, as well as for their ability to induce autophosphoryation of VEGFR-3 as previously described [11] .
Cloning of the human mature VEGF-C (VEGF-CDNDC)
The human VEGF-CDNDC cDNA sequence spanning Thr 103 to Arg 227 [29] was amplified by PCR from pooled human cDNA (Clontech, Mountain View, CA) and cloned into pCR2.1 TOPO (Invitrogen, Carlsbad, CA). The insert was then subcloned into pSecTag 2B (Invitrogen) using the BamHI and EcoRI sites included in the amplification primers. The cDNA was further cloned into the expression vector pGS-His using MluI and PmeI restriction sites. The protein was expressed by transiently transfecting the expression vector into HEK293 cells and purified from the supernatant of pooled cells by nickel chromatography.
VEGFR-3-alkaline phosphatase fusion proteins
Preparation of the human VEGFR-3 soluble extracellular domain alkaline phosophatase (AP) fusion protein has been previously described [30] . For the equivalent rat VEGFR-3 soluble extracellular domain, rat liver mRNA was reversetranscribed. The cDNA encoding Ig domains 1-7 in the extracellular domain of rat VEGFR-3 was amplified by PCR and cloned into the expression vector pGS-His. HEK293 cells were transfected with the appropriate expression vectors, and VEGFR-3-AP fusion protein (sR3-AP) was purified from the medium using a nickel column.
Quantitative VEGFR-3 binding assay Antibodies were added to 96-well Maxi-sorp microtiter plates coated with human or rat sR3-AP and incubated at RT for 1 h. Bound IgG was detected by incubating the plates at RT for 1 h with rabbit anti-human or rabbit antirat IgG-HRP (Jackson Immunoresearch, West Grove, PA). The plates were washed and amount of binding was quantified in a luminometer after adding BM chemiluminescence ELISA reagent (Roche).
Competitive VEGF-C blocking assay Various amounts of antibodies were incubated with 50 ng of respective sR3-AP for 1 h, then transferred to 96-well microtiter plates coated with 200 ng/well of the mature form of human VEGF-CDNDC. After 2 h, the plates were washed five times with PBST. Binding of the soluble receptors was detected with a mouse anti-6HIS tag monoclonal antibody conjugated with HRP, and quantified using a luminometer and chemiluminescence ELISA reagent.
Evans blue dye injections
For the visualization of lymph node drainage from the no. 4 mammary gland, 100 ll of Evans blue dye (2.5 mg/ml in PBS) were injected into the no. 4 mammary fat pad of female w/Fu rats aged between 8 and 10 weeks. The rats were sacrificed 2 h later, and the skin and lymph nodes were exposed and photographed. For assessment of lymphatic drainage in the context of tumors, MT-450 cells (10 6 cells in PBS) were injected into the no. 4 mammary fat pad of w/Fu rats aged between 8 and 10 weeks. Tumors were allowed to grow for 18 days, then the rats were intradermally injected under isoflurane anaesthesia with 150 ll Evans blue dye at the level of the lower rib cage on the flank laterally from the midline, using microneedle-based rodent intradermal delivery devices. The skin, tumor and lymph nodes were exposed 1.5 h post injection and photographed.
Intradermal injections of recombinant VEGF-C or VEGFR-3 antibodies
Intradermal injections at the level of the lower rib cage on the flank laterally from the midline were performed under isoflurane anaesthesia on normal or tumor-bearing w/Fu rats aged between 8 and 12 weeks using microneedle-based rodent intradermal delivery devices. Injections were performed five times per week (Monday-Friday). At the end of the experiments, the lymph nodes draining the injected area were excised; their size measured, then analyzed using immunohistochemistry as described above. Lymph nodes contralateral to the injected side and from PBS-injected animals served as controls. VEGF-C and Serum Amyloid A (SAA) in serum from the animals were quantified by ELISA using the rat VEGF-C kit BMS626/2 (Bender MedSystems) and the SAA kit (ALPCO Diagnostics) according to the manufacturer's instruction.
Statistics
Unpaired two-tailed t tests were used to calculate p values. Differences were considered to be significant if the calculated p value was B0.05.
Results
MT-450 tumors induce lymphangiogenesis in their draining lymph nodes
Poorly metastastic NM-081 rat breast tumors are associated with few if any lymphatic vessels, while highly metastatic MT-450 tumors are characterized by the presence of many vessels both in peri-tumoral and intra-tumoral areas, as revealed by LYVE-1 and Prox-1 immunostaining ( [16] and Supplementary Fig. 1 ). We have previously shown that the high LVD associated with MT-450 tumors is dependent on tumor-derived VEGF-C [16] . Accordingly, we found that interstitial fluid isolated from these tumors is enriched for VEGF-C compared to the VEGF-C levels found in normal rat serum (920.09 ± 135.77 pg/ml (n = 5) in MT-450 tumor interstitial fluid compared to 256.24 ± 30.30 pg/ml (n = 5) in rat serum). As tumor interstitial fluid drains to regional lymph nodes, we reasoned that tumor-derived VEGF-C may act in these lymph nodes, for example by inducing LNL and/or metastasis formation.
As a first step towards investigating this hypothesis, we ectopically expressed mCherry red fluorescent protein in NM-081 and MT-450 tumor cells so that we could track their entry into tumor-draining lymph nodes and other organs. We first ensured that mCherry expression had no effect on the tumor growth and metastatic properties of the transfected cells ( Supplementary Fig. 2 ). Next, mCherry MT-450 and NM-081 cells were orthotopically implanted into rats, and the animals were sacrificed 2, 3 and 4 weeks after tumor cell implantation. The tumor-draining axillary lymph nodes were then taken, and LVD and the presence of tumor cells were assessed.
For both MT-450 and NM-081 tumors, no tumor cells could be found in either the axillary draining lymph nodes or in other organs of the animals two weeks post implantation ( Fig. 1 ). However, a marked increase in LVD as evidenced by LYVE-1 staining was observed in the lymph nodes draining the MT-450 tumors at this time point (Fig. 2) . Staining of these samples for Prox-1 confirmed that the increased LYVE-1 staining reflects increased LVD (Fig. 3) .
Three weeks after tumor cell implantation, MT-450 cells began to colonize the axillary lymph nodes draining them, whereas no such colonization was observed for NM-081 cells. At this time point, the MT-450 tumor cells were mainly localized in the subcapsular sinus and the cortex of the lymph node ( Fig. 1) . Small metastases were also observed in the lungs of these animals at this time point ( Supplementary  Fig. 3 ). Importantly, the LVD in the lymph nodes draining the MT-450 tumors became even more pronounced at this time point, while no changes in the LVD of lymph nodes draining the NM-081 tumors were observed (Fig. 2) . Four weeks after tumor cell implantation, mCherryexpressing MT-450 cells were found not only in the subcapsular sinus of the lymph nodes, but had also invaded extensively and compromised the architecture of the invaded nodes (Fig. 1a) . Disseminated tumor cells were often found in tight association with the expanded lymphatic vasculature (Fig. 1b) . Furthermore, the lungs of these MT-450 tumor-bearing animals were widely infiltrated by confluent metastases at this time point (Supplementary Fig. 4) . Conversely, even when NM-081 tumors were allowed to grow for several weeks more until they reached the German legal limit of 5 cm in one dimension, only 5/18 rats were found to have any detectable metastatic deposits in their regional lymph nodes.
Together, these data suggest that as with other tumor models [23] , MT-450 tumors induce lymphangiogenesis in their draining lymph nodes in advance of metastatic colonisation of the lymph nodes, and that this LNL becomes further augmented once tumor cells begin to colonise the lymph nodes.
Lymph node lymphangiogenesis does not suffice to induce metastasis of NM-081 cells
We have previously shown that ectopic expression of VEGF-C in NM-081 cells stimulates lymphangiogenesis around the primary tumor, and is sufficient to induce metastasis of NM-081 tumors to both regional lymph nodes and to the lungs [16] . To determine whether the activity of VEGF-C in lymph nodes suffices to initiate metastasis formation, we first established conditions that allow specific delivery of recombinant VEGF-C to axillary lymph nodes, using induction of lymphangiogenesis in these lymph nodes as a read-out for VEGF-C activity. Lymphatic access has traditionally been obtained through difficult direct canulation or through inefficient subcutaneous or Mantoux-style intradermal delivery. In this study, we utilized a specialized microneedle delivery device (BD Technologies, RTP, NC, USA) that reproducibly targets the intradermal space. Delivery of compounds using these devices has been shown to preferentially target the draining lymph nodes and significantly increase lymphatic uptake compared to standard delivery techniques [31] .
The patterns of lymphatic drainage in the rat have been studied intensively [32, 33] . In the flank lymphatic fluid drains unidirectionally in a caudal-rostral direction. The caudal axillary lymph node receives lymphatic fluid from the upper-mid flank, the nipples and the inguinal nodes. Thus tumors growing in the no. 4 mammary fat would be expected to drain to the ipsilateral caudal axillary lymph node. Similarly, any fluid injected intradermally laterally from the midline at the level of the lower rib cage on the upper flank should drain to the same caudal axillary lymph node without draining to tumors growing in the no. 4 mammary fat. To verify that this is the case in the w/Fu rat strain, first we injected Evan's blue dye into the no. 4 mammary fat pat to track its lymphatic drainage. As can be seen in Fig. 4 , the dye drains into the large efferent channel that follows the superficial epigastric vein along the milk (Fig. 4d) . Note that no dye was observed in the inguinal nodes (Fig. 4b) , showing that the no. 4 mammary fat pad region drains directly to the caudal axillary lymph node.
Next we implanted MT-450 tumor cells into the no. 4 mammary fat pad and allowed the primary tumor to grow for 18 days. We then injected Evan's blue dye intradermally laterally from the midline at the level of the lower rib cage (Fig. 5) . The dye again drains into the efferent channel that follows the superficial epigastric vein (Fig. 5c ) and enters the caudal axillary lymph node (Fig. 5b) . Note that as expected there is no retrograde lymphatic fluid flow to the primary tumor (Fig. 5d) , and that drainage from the intradermal injection site to the axillary node is not disturbed by the presence of the tumor. Thus by intradermal injection laterally from the midline at the level of the lower rib cage, it is possible to specifically target the caudal axillary lymph node that receives tumor cells draining from tumors growing in the no. 4 mammary glands.
Rats were injected intradermally in the flank for three weeks with either recombinant fully processed rat VEGF-C protein (VEGF-C DNDC) or the VEGFR-3-specific point mutant thereof (VEGF-C DNDC Cys) that we have previously described [11] , which is the mouse/rat homolog of the human VEGF-C C156S mutant [10] . This resulted in a pronounced lymphangiogenesis in the axillary lymph nodes draining the site of injection, resulting in an augmented LVD similar to that induced by MT-450 tumors three weeks post injection of tumor cells (Fig. 6 ). In contrast, we did not observe any change in blood vessel density (Fig. 6b) . No differences in the levels of VEGF-C in the blood of VEGF-C-injected animals compared to controls could be detected in ELISA assays (Fig. 6c) , ruling out potential systemic effects of the injected VEGF-C. Furthermore, no increase in SAA levels in the blood of VEGF-C-injected animals was detected ( Supplementary Fig. 4) , indicating that the injection regime did not result in an overt inflammatory reaction.
Using these conditions, we next determined whether the activity of VEGF-C in tumor-draining lymph nodes is sufficient to induce metastasis in the NM-081 tumor model. NM-081 tumor cells were injected into the 4th mammary fat pads of w/Fu rats. VEGF-C DNDC was injected intradermally for a period of four weeks downstream of the lymphatics draining the growing primary tumor. This allowed us to induce lymphangiogenesis in the axillary lymph nodes draining the tumors without inducing lymphangiogenesis in the tumors themselves. In other groups of rats, PBS and rat serum albumin were injected intradermally as controls. At autopsy, no significant difference in the frequency of either lymph node and lung metastasis formation in the VEGF-C DNDC-injected animals compared to the PBS or albumin-injected control group was observed (Fig. 6d) . The stimulation of lymph node lymphangiogenesis in the NM081 tumor-bearing animals by the intradermally injected VEGF-C was verified Fig. 5 ). As ectopic expression of VEGF-C in NM-081 tumor cells suffices to induce both peritumoral lymphangiogenesis, as well as metastasis to lymph nodes and lungs [16] , these data suggest that in the absence of primary tumor lymphangiogenesis, the activity of VEGF-C in the tumor-draining lymph nodes does not suffice to promote metastasis formation in this model. Specific inhibition of VEGF-C activity in lymph nodes draining MT-450 tumors suppresses the outgrowth of lymph node metastases but has no effect on lung metastasis formation To determine whether LNL plays a role in metastatic dissemination in the MT-450 model, we used an anti-VEGFR-3 antibody that blocks ligand-induced activation of VEG-FR-3 [30] . This allowed us to suppress activation of VEGFR-3 by VEGF-C and VEGF-D, both of which are produced by MT-450 tumors [16] . The anti-VEGFR-3 antibody was raised against human VEGFR-3, but recognises an epitope that is conserved in rat VEGFR-3 ( Fig. 7a) and blocks VEGF-C-mediated activation of rat VEGFR-3 (Fig. 7b) . MT-450 cells do not express VEGFR-3, and accordingly the anti-VEGFR-3 antibody did not stain MT-450 cells in FACS analysis (Fig. 7c) , ruling out direct inhibitory effects of the antibody on the tumor cells.
MT-450 tumor cells were injected into the 4th mammary fat pad of w/Fu rats. Either 50 lg (Fig. 8) or 25 lg (Fig. 9 ) of the antagonist anti-VEGFR-3 antibody were then injected intradermally five times per week into the lymphatic drainage basin downstream of the tumor injection site, so that the injected antibody drained to the axillary lymph nodes but did not access the primary tumor. Antibody treatment began immediately following injection of the tumor cells into the rats. Different groups of animals were treated for 2, 3 and 4 weeks in this way. PBS and anti-KLH isotype control antibodies were also injected into other groups of tumorbearing animals as controls. No differences in tumor growth were found among the groups (Fig. 8a) , and the lymphatic vascular density in the primary tumors of the different groups was also unaffected (Fig. 8b, c) . Thus the intradermal injection of low doses of the anti-VEGFR-3 antibody did not interfere with primary tumor development, nor with tumor-induced lymphangiogenesis in the primary tumor. At each time point, axillary lymph nodes were analysed for LVD. The development of metastases in the lymph nodes was assessed by monitoring lymph node volume and quantification of metastatic mCherry-positive tumor cells within the lymph nodes. Equivalent results were obtained in the 25 and 50 lg regime experiments. After two weeks tumor growth, the anti-VEGFR-3 antibody treatment efficiently blocked tumor-induced lymphangiogenesis, reducing it to the levels observed in control animals (Fig. 9a) . After three weeks tumor growth, a time when tumor cells have started to colonise the lymph nodes (Fig. 1) , lymph node volumes increased in comparison to those from nontumor-bearing animals (Fig. 9b) , corresponding to the presence of metastatic tumor cells in the lymph nodes (Fig. 9c) . At this time point, however, when lymph nodes from anti-VEGFR-3 antibody-treated rats were compared to lymph nodes from the animals treated with the anti-KLH antibody or with PBS, there were no differences in either the volume of the lymph nodes or the number of metastatic cells in the lymph nodes (Fig. 9b, c) . Strikingly, however, when the same analysis was performed after four weeks of tumor growth and antibody treatment, we found that both the lymph node volume and the metastatic tumor burden present in the lymph nodes was significantly reduced in the anti-VEGFR-3 antibody-treated animals compared to the controls (Figs. 8d, 9b, c) . Tumor-induced lymphangiogenesis and metastatic outgrowth in the lymph nodes was blocked to a similar extent with either the 25 or 50 lg antibody regime, suggesting that the 25 lg dose regime of the anti-VEGFR-3 antibody was already sufficient to b Fig. 6 Induction of lymphangiogenesis in axillary lymph nodes does not promote metastasis formation by NM-081 tumors. Intradermal injection of recombinant VEGF-C proteins into the flank of nontumor-bearing animals was used to induce lymphangiogenesis in the axillary lymph nodes. a Lymph node sections from control animals (Ctrl) or from animals treated with either VEGF-C DNDC or VEGF-C DNDC Cys proteins were immunostained for LYVE-1 (red fluorescence) and CD31 (green fluorescence). The right panels are a magnification of the panels of the left. The scale bar represent 500 lm for the panels on the left side, and 100 lm for the panels on the right side. b Quantification of the area of the ipsilateral axillary lymph nodes that stained positively with the anti-LYVE-1 antibody and with the anti-CD31 antibody. The mean ± SEM of the positively stained area (%) from five rats and four complete lymph node sections per rat is shown for untreated control (Ctrl) animals and for animals treated with the indicated proteins. *p B 0.05 compared to control using the students t test. c Quantification of VEGF-C levels in serum taken from control (Ctrl) (n = 5), VEGFC DNDC (n = 5) and VEGF-C DNDC Cys (n = 5) treated animals. The mean ± SEM for five animals is presented. d NM-081 tumor-bearing animals were injected intradermally in the flank with the indicated proteins for four weeks. The injection site was located between the tumor growing in the 4th mammary fat pad and the axillary lymph node draining the tumor. Primary tumor take rate and the incidence of metastasis in the draining axillary lymph node and in the lungs were then assessed inhibit maximally the LNL induced by MT-450 tumors and the subsequent outgrowth of disseminated tumor cells in the node. No analogous reduction in lung metastasis formation was observed in these experiments. There was no significant difference in the number of metastatic lung nodules amongst the different groups after three weeks tumor growth (Fig. 9d) . After four weeks, the lungs of both anti-VEGFR-3 antibody-treated rats and controls were equivalently infiltrated by confluent metastases (Fig. 9e) . Similar to the case with the 25 lg dose regime, the 50 lg dose regime had no effect on lung metastasis formation compared to controls.
These results suggest that specific inhibition of VEGF-C activity in the lymph nodes draining MT-450 tumors suppresses tumor-induced LNL and metastatic outgrowth of disseminated tumor cells in the lymph nodes. However, it does not affect the initial colonisation of the lymph nodes by the tumor cells, and has no effect on lung metastasis formation.
Discussion
Here we have used syngeneic breast cancer models to dissect the role that the activity of VEGF-C in tumor-draining lymph Binding was detected using HRP-conjugated secondary antibodies and measured by luminescence intensity (LU) as described in the ''Materials and Methods'' section. The antibody bound to immobilized extracellular domain of mouse (triangles) VEGFR-3 with a 50-fold higher EC 50 (3.3 nM), in agreement with very low cross reactivity with the mouse VEGFR-3 receptor. b In competitive VEGF-C binding assays, the antagonist antibody to human VEGFR-3 inhibited binding of VEGF-CDNDC to immobilized extracellular domains of human (circles) and rat (squares) VEGFR-3. Binding was detected using HRP-conjugated secondary antibodies and measured by luminescence intensity (LU) as described in the ''Materials and Methods'' section. The potency of inhibition (IC 50 ) was similar for human (5.6 nM) and rat (11 nM) VEGFR-3. c Flow cytometry analysis showing that the anti-VEGFR-3 antibody does not bind to MT-450 cells. Cells were stained with either anti-KLH isotype control antibody (KLH-Ab) or the human monoclonal antagonist antibody against VEGFR3. As a positive control, human primary LECs were used. Live cells were gated, and the percentage of cells in the gate staining positive was calculated. Fluorescence intensity of antibody staining (FITC-A) against sideward scatter (SSC) is plotted nodes plays in metastasis formation. We found that VEGF-C induces LNL, but that this is not sufficient to initiate metastasis formation by poorly metastatic NM-081 tumors. However, inhibition of VEGFR-3 activation in the lymph nodes draining metastatic MT-450 tumors that produce VEGF-C and VEGF-D [16] suppressed the outgrowth of lymph node metastases, but had no effect on metastasis formation in other organs such as the lung. Together these data demonstrate that tumor-derived VEGF-C can act regionally in lymph nodes to foster metastasis formation, in addition to its local pro-lymphangiogenic role in the primary tumor microenvironment.
Similar to other studies [23, 24, 34, 35] , we found that LNL preceded colonization of tumor cells in the sentinel nodes draining primary tumors. However, not all studies with VEGF-C-overexpressing tumor models have observed induction of lymph node lymphangiogensis prior to lymph node invasion by tumor cells [36] , perhaps due to the anatomical location of the primary tumor relative to the draining lymph nodes, or to differences in the relative expression levels of VEGF-C in the tumor models used.
Previously we reported that ectopic expression of VEGF-C in NM-081 tumors increases lymphangiogenesis in the primary tumor and promotes metastasis formation in regional lymph nodes and lungs [16] . However, we report here that specific induction of LNL did not suffice to promote metastasis formation by NM-081 tumors, despite the fact that a LVD equivalent to that induced by MT-450 tumors and which supports lymph node metastasis outgrowth was achieved. These data therefore suggest that in this model, tumor-induced LNL without an effective lymphangiogenesis in the primary tumor is not sufficient to stimulate metastasis formation in the regional draining lymph nodes, nor in other organs. This observation underscores the potential of lymphangiogenesis in the primary tumor to increase tumor cell entry into the lymphatics, thereby supporting lymph node metastasis formation. We found that the density of LYVE-1-positive cells increased significantly in response to VEGF-C in lymph nodes. Conceivably some of this increase in LYVE-1 staining could be due to the presence of LYVE-1-positive cells other than lymphatic endothelial cells (LECs), for example macrophages. However, Prox-1 staining revealed a similarly increased LVD in lymph nodes in response to Fig. 9 Inhibition of tumor-induced lymph node lymphangiogenesis suppresses the outgrowth of MT-450 metastases in the lymph node but not the lung. Tumor-induced lymphangiogenesis in the axillary lymph nodes draining MT450 primary tumors was inhibited using intra-dermal injection of the VEGFR-3 blocking antibody (25 lg/ injection). Groups of five animals with MT-450 tumors growing in the 4th mammary fat pads were injected intradermally in the flank with either PBS (Ctrl-PBS), isotype anti-KLH control antibody (KLH-Ab) or the VEGFR-3 blocking antibody for the indicated times post implantation of the tumor cells. The injection site was located between the tumor and the axillary lymph node draining the tumor. a Quantification of the area of the ipsilateral axillary lymph nodes that stained positively with the anti-LYVE-1 antibody two weeks posttumor implantation and antibody treatment. The mean ± SEM of the LYVE-1 ? area (%) from five rats and four complete lymph node sections per rat is shown for the axillary lymph nodes ipsilateral (Ipsi) and contralateral (Contra) to the tumors. *p B 0.05 compared to contralateral lymph nodes using the students t test. b Quantification of the volume (mm 3 ) of the ipsilateral axillary lymph nodes. Analyses were performed at the indicated time points post implantation (p.i.) of the tumor cells into the mammary glands/commencement of the intradermal injections. Data are presented as mean ± SEM for five animals. *p B 0.05 compared to control lymph nodes using the students t test. One-way ANOVA analysis also showed a statistically significant difference between the three groups at 4 weeks (p = 0.0318). c The area of each lymph node section occupied by mCherry-positive tumor cells was quantified as a percentage in the axillary lymph nodes ipsilateral to the MT-450 tumors. Analyses were performed at the indicated time points post implantation (p.i.) of the tumor cells into the mammary glands/commencement of the intradermal injections. Data are presented as mean ± SEM for five animals and four complete lymph node sections per rat. *p B 0.05 compared to control lymph nodes using the students t test. One-way ANOVA analysis also showed a statistically significant difference between the three groups at 4 weeks (p = 0.0489). d Quantification of metastatic lung nodules in animals after three weeks of tumor growth and antibody treatment. Data are presented as mean ± SEM for five animals. e Representative pictures showing confluent lung metastasis after 4 weeks growth of MT-450 tumors with concomitant intradermal delivery of either PBS or anti-VEGFR-3 antibodies as indicated VEGF-C, comparable to that observed with LYVE-1. Thus a major effect of VEGF-C in tumor-draining lymph nodes is to promote LNL. This could be decisive for the promotion of the outgrowth of metastases by VEGF-C in lymph nodes. For example, recent studies suggest that LECs can participate in antigen cross-presentation in lymph nodes, thereby stimulating immune tolerance to tumor cells [37] . In addition, lymphatic vessels may be a component of the metastatic niche, a microenvironment that is conducive for the outgrowth of disseminated tumor cells as overt metastases [4, 20, 35, 38] . Consistently, a perivascular location supports the survival and outgrowth of disseminated tumor cells [39] . Furthermore, cancer stem cell maintenance in the brain [40] and the skin [41] requires a perivascular location. Moreover, endothelial cell-secreted factors can enhance the survival and self-renewal of cancer stem cells [42] . Thus an increased density of perivascular niches due to tumor-induced LNL may in this way foster the outgrowth of lymph node metastases. Indeed, we observed a tight apposition of disseminated MT-450 tumor cells with the expanded lymphatic vascular in lymph nodes, often with a perivascular location (Fig. 1b) . Support for this notion is also possibly provided by studies in which administration of an antibody that blocks VEGFR-3 activation reduced lymph node metastasis outgrowth and suppressed lymphangiogenesis in a breast cancer model, even when the antibody treatment was initiated after metastases were already established [43] .
The experiments here do not allow us to exclude the possibility the VEGF-C acts on cells in the lymph node other than LECs, such as VEGFR-3-expressing CD14? monocytes [44] . Nevertheless, in our loss and gain of function experiments, we observed no effect on the density of CD31? blood endothelial cells. These data are consistent with other findings that demonstrate a specific effect of VEGF-C on lymphatic but not blood endothelium in the tumor context [23, 45] .
Lung metastases spawned by MT-450 primary tumors must have been originally seeded by blood-borne tumor cells as there are no direct lymphatic connections between the lung and the mammary gland/flank. Cells from the primary tumor can in principle enter directly into the blood stream, or disseminate through the lymphatics, with subsequent entry into the blood stream via anastomoses such as the thoracic duct. Lymph node metastases initiated by tumor cells disseminating via the lymphatics could also conceivably shed tumor cells that subsequently enter the blood stream and seed metastases. The experimental design we used here allowed us to examine the impact of inhibiting lymph node lymphangiogenesis on lung metastasis formation by MT-450 tumors. Although specific inhibition of VEGFR-3 activation in lymph nodes suppressed lymph node lymphangiogenesis and the outgrowth of lymph node metastases, no effect on lung metastasis formation was observed. This may suggest that MT-450 lung metastases are seeded in the main by tumor cells that traffic from the primary tumor directly via the blood stream. However, we have shown previously that VEGF-C expression by the primary tumor clearly fosters lung metastasis in the MT-450 model [16] . Thus VEGF-C may promote lung metastasis via a mechanism that is independent of its effects on lymph node metastasis formation. Studies on human rectal tumors also suggest that distant metastasis formation can be independent of tumor-induced LNL and lymph node metastasis, as LVD in regional nodes strongly correlated with lymph node metastasis formation, but had no correlation with distant metastasis [46] . We also note that VEGFR-3 is expressed on and regulates bone marrowderived cells such as megakaryocyte progenitors [47] and CD14? monocytes [44] that have been implicated in pulmonary metastasis formation [48] . Thus VEGF-C could conceivably act systemically to promote metastasis in organs such as the lungs by activating VEGFR-3 not only on LECs but also on other VEGFR-3-expressing cells [4] . Consistently, a recent study reported that when intraperitoneal administration of anti-VEGF-C inhibitory antibodies (at more than two orders of magnitude higher doses than those employed in our study) was initiated after removal of a primary glioblastoma xenograft, the outgrowth of lung metastases was suppressed [49] . Interestingly, this treatment also mitigated tumor-induced remodeling of the lymphatics distal to the sentinal nodes, leading to normalization of lymph transport. Future work will focus on understanding how VEGF-C promotes metastasis to organs other than the lymph node.
The human anti-human VEGFR-3 antibody used in this study blocks ligand-induced activation of human VEGFR-3 [30] . Here we show that the antibody has similar inhibitory activity against rat VEGFR-3. The observation that the anti-VEGFR-3 antibody is able to inhibit tumor-induced LNL and to suppress metastatic outgrowth in a syngeneic rat model of metastatic breast cancer therefore provides a rationale for the therapeutic use of this antibody in human cancer patients.
Our data and that of others suggest that LNL in sentinel nodes acts as a measure of active VEGF-C being produced by the primary tumor. This observation may have potential clinical application. While regional lymph node metastasis is an important prognostic indicator for many different types of cancer [4] , node negativity is not a perfect correlate with good prognosis. Assessment of LNL in sentinel lymph nodes in which disseminated tumor cells cannot be detected may therefore allow stratification of lymph node negative patients into those with good or bad prognosis. Indeed, first studies in this direction with pancreatic [35] and rectal [46] cancer patients have reported a correlation in node-negative patients between poor prognosis and higher LVD in the sentinel nodes. Further work is required to substantiate whether evaluation of LVD in the sentinel nodes of nodenegative patients will be a useful prognostic tool.
